The aim of the present study determines the effect of zinc and melatonin supplementation on IL-6 levels in female rats with breast cancer induced by DMBA (7,12-Dimethylbenz[a]anthracene). Total 42 wistar female rats which was just weaned from milk equally separated 5 groups. Group 1 control, Group 2 DMBA control, Group 3 DMBA+Zinc, Group 4 DMBA+Melatonin, Group 5 DMBA+Zinc+Melatonin. To induce breast cancer, the animals, except those in group 1, were administered 80 mg/kg of DMBA in colza oil (canola) through gavage. The groups which were supplemented with zinc and melatonin were introperitoneally given 5 mg/kg/day of zinc, melatonin and zinc+melatonin for 4 weeks. Blood samples were taken under general anesthesia to tube with EDTA, and IL-6 levels were determined by ELISA. The highest IL-6 levels were determined in the DMDA control group (p<0.05). DMBA + zinc and DMBA+ melatonin groups were had lower IL-6 levels compared to group 2 (p<0.05). Group 5 has the lowest IL-6 levels compared to all breast cancer induced groups (G 2,3,4) (p<0.05). The results of the present study indicate that increased IL-6 levels in breast cancer inhibites by zinc and melatonin. However, the most significant inhibition was seen in combine of zinc and melatonin (group 5). The combined administration of zinc + melatonin may contribute to the prevention of tumoral growth by suppressing IL-6 levels, which can accelerate cancer development.
Eser Adı (dc.title) | Increased IL-6 Levels Inhibites by Zinc and Melatonin Support in Rats with Breast Cancer induced by DMBA |
Yayın Türü (dc.type) | Konferans Bildirisi |
Yazar/lar (dc.contributor.author) | BALTACI, Saltuk Buğra |
Yazar/lar (dc.contributor.author) | GÜLBAHÇE MUTLU, Elif |
Yazar/lar (dc.contributor.author) | MOĞULKOÇ, Rasim |
Yazar/lar (dc.contributor.author) | BALTACI, Abdülkerim Kasım |
Atıf Dizini (dc.source.database) | Diğer |
Konu Başlıkları (dc.subject) | DMBA |
Konu Başlıkları (dc.subject) | Breast Cancer |
Konu Başlıkları (dc.subject) | IL-6 |
Konu Başlıkları (dc.subject) | Zinc |
Konu Başlıkları (dc.subject) | Melatonin |
Yayıncı (dc.publisher) | Internatıonal Academic Research Congress (INES-2018) |
Yayın Tarihi (dc.date.issued) | 2018 |
Kayıt Giriş Tarihi (dc.date.accessioned) | 2019-07-10T08:50:43Z |
Açık Erişim tarihi (dc.date.available) | 2019-07-10T08:50:43Z |
Özet (dc.description.abstract) | The aim of the present study determines the effect of zinc and melatonin supplementation on IL-6 levels in female rats with breast cancer induced by DMBA (7,12-Dimethylbenz[a]anthracene). Total 42 wistar female rats which was just weaned from milk equally separated 5 groups. Group 1 control, Group 2 DMBA control, Group 3 DMBA+Zinc, Group 4 DMBA+Melatonin, Group 5 DMBA+Zinc+Melatonin. To induce breast cancer, the animals, except those in group 1, were administered 80 mg/kg of DMBA in colza oil (canola) through gavage. The groups which were supplemented with zinc and melatonin were introperitoneally given 5 mg/kg/day of zinc, melatonin and zinc+melatonin for 4 weeks. Blood samples were taken under general anesthesia to tube with EDTA, and IL-6 levels were determined by ELISA. The highest IL-6 levels were determined in the DMDA control group (p<0.05). DMBA + zinc and DMBA+ melatonin groups were had lower IL-6 levels compared to group 2 (p<0.05). Group 5 has the lowest IL-6 levels compared to all breast cancer induced groups (G 2,3,4) (p<0.05). The results of the present study indicate that increased IL-6 levels in breast cancer inhibites by zinc and melatonin. However, the most significant inhibition was seen in combine of zinc and melatonin (group 5). The combined administration of zinc + melatonin may contribute to the prevention of tumoral growth by suppressing IL-6 levels, which can accelerate cancer development. |
Yayın Dili (dc.language.iso) | en |
Tek Biçim Adres (dc.identifier.uri) | https://hdl.handle.net/20.500.12498/1076 |